Comparison of Levofloxacin versus Moxifloxacin for Multidrug-Resistant Tuberculosis

Won-Jung KohSeung Heon LeeYoung Ae KangChang-Hoon LeeJae Chol ChoiJae Ho LeeSeung Hun JangKwang Ha YooKi Hwan JungKi Uk KimSang Bong ChoiYon Ju RyuKyung Chan KimSoojung UmYong Soo KwonYee Hyung KimWon-Il ChoiKyeongman JeonYong Il HwangSe Joong KimYoung Seok LeeEun Young HeoJuhee LeeYeo WoonKiTae Sun ShimJae-Joon Yim
Dept. of Internal Medicine (내과학)
Issue Date
American Journal of Respiratory and Critical Care Medicine, Vol.188(7) : 858-64, 2013
Rationale: Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. Objectives: To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB. Methods: In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen. The primary outcome was the proportion of patients who achieved sputum culture conversion at 3 months of treatment. Secondary outcomes were time to culture conversion and time to smear conversion, with data censored at 3 months, and the proportions of adverse drug reactions. Measurements and Main Results: At 3 months of treatment, 68 (88.3%) of the 77 patients in the LFX group and 67 (90.5%) of the 74 in the MXF group showed conversion to negative sputum cultures (odds ratio for LFX compared with MXF, 0.78; 95% confidence interval, 0.27–2.20). Adverse drug reactions were reported in six patients (7.7%) in the LFX group and four (5.2%) in the MXF group (P = 0.75). Conclusions: The choice of LFX or MXF for treatment of patients with MDR-TB may not affect sputum culture conversion at 3 months of treatment. Clinical trial registered with (NCT 01055145). KEYWORDS: multidrug-resistant tuberculosis, fluoroquinolone, moxifloxacin, levofloxacin Read More:
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
Full Text
File in this Item
 사서에게 요청하기
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.